Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2012

View Archived Issues

EE-TP shows promise for the treatment of MNGIE

New DNA supercoiling inhibitors for bacterial infections presented by Biota

Kalidex conducts phase I study of novel fluoroquinolone antibiotic

Teijin Pharma gains rights to investigational bronchial asthma drug

ASSURE trial of RVX-208 completes enrollment

Cannabis Science initiates European preclinical program for CS-TATI-1

Prozymex presents novel dipeptidyl peptidase 1 inhibitors

Chinese researchers synthesize new androgen receptor antagonists

Abbott launches Absorb bioresorbable vascular scaffold

Sanofi discloses several new agents for diabetes

Reckitt Benckiser to discontinue supply of Suboxone tablets in U.S.

Array BioPharma and Genentech report novel ERK inhibitors

Forest Laboratories submits NDA for levomilnacipran

Pharming completes phase III Ruconest study

FDA grants priority review status to sNDA for Amitiza

Bristol-Myers Squibb files application in Japan for Taxol for germ cell tumors

FDA acknowledges receipt of NDA resubmission for Eliquis

Pfizer and Acura Pharmaceuticals terminate license agreement

FDA accepts NDA for FF/VI for COPD

EMA recommends approval of ingenol mebutate for actinic keratosis

UCB's phase IIb study of olokizumab meets primary endpoint

Positive results reported from phase Ib trial of ACH-3102

BioMarin to start phase III program for PEG-PAL in 2013

Merck & Co. returns vernakalant rights

FDA approves Bayer's Stivarga for treatment of metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...